TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01102101
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil (Ultiva; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to approx. 0.7 µg kg-1 min-1.
Study: NCT01313585
Drug: Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device
Normalized name: salbutamol and beclometasone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01106079
Drug: Intensive management or Tight control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Those subjects randomised to the intensive management or tight control arm will be reviewed every 4 weeks (by the Principal Investigator at each site or a designated researcher) and will be treated according to a rapidly escalating regime, involving standard DMARDs and biologics. Initial therapy will be with oral methotrexate, increasing in dose rapidly over the first 8 weeks of the study. From the 12 week visit onwards, escalation of therapy in this arm will be performed if subjects do not meet the objective target of Minimal Disease Activity. Initial escalation will be to combination DMARD therapy. If patients in the tight control arm fail to meet the MDA criteria and fulfil the NICE criteria for the use of TNF blockers in psoriatic arthritis at 24 weeks, then they will be offered treatment with these medications. Therapy will continue to be modified throughout the 48 week follow-up until a state of minimal disease activity is reached.
Study: NCT00747032
Drug: NYC 0462 Ointment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
Study: NCT00747032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
Study: NCT02477618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02680054
Drug: Insulin, Asp(B28)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
Study: NCT03053050
Drug: Placebo to match SEL 6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT03053050
Drug: Placebo to match SEL 18 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT03656744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets manufactured to mimic HTD1801 tablets
Study: NCT00104572
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 12 months
Study: NCT00104572
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 12 months
Study: NCT04521738
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Study: NCT01651000
Drug: CTAP101 30 μg capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTAP101 30 μg capsule taken daily at bedtime.
Study: NCT01707329
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
Study: NCT01899859
Drug: GR-MD-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR-MD-02; galactoarabino-rhamnogalaturonate
Study: NCT01899859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR-MD-02 Placebo
Study: NCT02192398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo).
Study: NCT02234492
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comparison of rosuvastatin to no rosuvastatin
Study: NCT03982186
Drug: Placebo for JNJ-73763989
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for JNJ-73763989 will be administered as subcutaneous injection.
Study: NCT04267432
Drug: Type 2 collagen
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control group
Study: NCT03714919
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative oral acetaminophen 15 mg/kg
Study: NCT03982186
Drug: Placebo for JNJ-56136379
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for JNJ-56136379 tablets will be administered orally.
Study: NCT03982186
Drug: Nucleos(t)ide Analog (NA)
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA treatment that is either of ETV, TDF or TAF tablets will be administered orally.
Study: NCT04247815
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet manufactured to match ATI-450 in appearance
Study: NCT04247815
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7.5 mg to 25 mg weekly
Study: NCT02593110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00549744
Drug: GSK256066
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04031755
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
Study: NCT04031755
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
Study: NCT01192867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally QD for 56 weeks
Study: NCT01192867
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.
Study: NCT01192867
Drug: Antipshychotics (Standard of Care)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
Study: NCT02171780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04646876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospective , comparative , double blind study
Study: NCT00822978
Drug: ACHN-490 Injection vs placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
Study: NCT00251745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
Study: NCT04202380
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive Azithromycin orally 1000 mg
Study: NCT04202380
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500 mg orally once
Study: NCT04202380
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 250 mg orally daily for 4 days
Study: NCT03071276
Drug: methotrexate/hydrocortisone/cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
Study: NCT00426439
Drug: Artemether-lumefantrine (Coartem)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, \< 34 kg: 4 tablets.
Study: NCT01748929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04429516
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule containing Microcrystalline Cellulose Ph. Eur, 5 mg twice daily
Study: NCT02732418
Drug: Depo-Provera CI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)
Study: NCT02732418
Drug: Depo-subQ 104
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA). Depo-subQ provera 104® (medroxyprogesterone acetate injectable suspension, 104 mg/0.65mL) for subcutaneous injection
Study: NCT04137042
Drug: Balanced crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative fluid therapy is administrated by using balanced crystalloid
Study: NCT00262665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
Study: NCT02216097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet taken once daily for 7 days.
Study: NCT02500602
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill
Study: NCT02170649
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02445599
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally 100 mg Diclofenac, administered 1 hour before surgery
Study: NCT02445599
Drug: bucain + fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.
Study: NCT02445599
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2nd choice for rescue analgetic 250ml intravenously
Study: NCT03654755
Drug: ASN002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of ASN002 for up to 110 weeks
Study: NCT04302012
Drug: Mydriatic Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects may be administered mydriatic medication to dilate their pupils.
Study: NCT01453179
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
Study: NCT02908087
Drug: Victoza® (liraglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
Study: NCT02908087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
Study: NCT02307773
Drug: Case Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consecutively, all the participants were assigned to case group with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope, same medication which was used for prior pharyngeal anesthesia, or to control group with conventional pharyngeal anesthesia without further treatment. Then we compared the primary outcome measures, such as, frequency of belching and retching of two groups.
Study: NCT04479644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given intravenously
Study: NCT03939663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: starch pills manufactured to mimic misoprostol 200 mg tablets
Study: NCT00797589
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02523300
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group
Study: NCT00226980
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00679133
Drug: MGCD265
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily administration; 7 days on / 7 days off
Study: NCT00732485
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, sugar pill, from admission to 6 months post burn
Study: NCT00451178
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
Study: NCT00451178
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
Study: NCT03189992
Drug: Bushen-Jianpi Dedoction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: A traditional chinese medicine prescription
Study: NCT03452137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion will be administered a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
Study: NCT02152605
Drug: UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg
Study: NCT02152605
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo
Study: NCT02271347
Drug: CMX001
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
Study: NCT03632915
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care
Study: NCT04898101
Drug: Microtracer [14C]ACP-196
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.
Study: NCT03750552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, QD
Study: NCT00299650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological serum infusion
Study: NCT02367911
Drug: 122-0551 Foam
Normalized name: Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 122-0551 Foam applied twice daily to treat psoriasis
Study: NCT02265562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 minutes before the surgery 2 tablet of placebo inserted rectally
Study: NCT02094417
Drug: AMG531
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous, weekly injection
Study: NCT00912938
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid 4mg over a minimum of 15 minutes in at least 100mls of calcium free infusion solution (0.9% sodium chloride or 5% glucose solution) every 4 weeks.
Study: NCT00293111
Drug: SDX-101 (R-Etodolac)
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03301649
Drug: Sklice® (Ivermectin) Lotion 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lotion, brand product.
Study: NCT03583476
Drug: Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
Study: NCT03929068
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given to maintain blinding of participants and study team.
Study: NCT06747026
Drug: RT with maintenance of ICI
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: For post-treatment progressive NSCLC, salvage radiotherapy performed during immunotherapy.
Study: NCT06747026
Drug: RT after discontinuation of ICI
Approvals — FDA: no, EMA: no, PMDA: no
Description: For post-treatment progressive NSCLC, salvage radiotherapy performed during within 90 days after the cessation of immunotherapy.
Study: NCT00132860
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00674739
Drug: placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo cream applied daily to wart areas for up to 8 weeks
Study: NCT00108134
Drug: PEP005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01092858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo i.m. injections at baseline, at week 6, at week 18 at week 30 and at week 42, respectively
Study: NCT04027101
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
Study: NCT01429077
Drug: levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
Study: NCT01429077
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
Study: NCT00280241
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.
Study: NCT00860392
Drug: Stable isotope tracer (13-C(4)-BHB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
Study: NCT03004339
Drug: SOR007 Ointment 2.0%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03004339
Drug: SOR007 Ointment 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03004339
Drug: SOR007 Ointment 0.15%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03004339
Drug: SOR007 Ointment Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03004339
Drug: Taclonex® Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00219817
Drug: RC-1291 HCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01557517
Drug: Placebo oral rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
Study: NCT04264676
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement of placebo oral tablet 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
Study: NCT05148377
Drug: Heptar
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
Study: NCT01607853
Drug: Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application, 3 weeks
Study: NCT01607853
Drug: Daivobet® gel applied for 24 hours (+/- 2 hours)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application, 3 weeks
Study: NCT00637494
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
Study: NCT02444910
Drug: KDT501
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg twice daily, Oral, for 10days; then 800mg twice daily, Oral, for 10 days; then 1,000mg twice daily, Oral, for 8 days.
Study: NCT00533312
Drug: Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04335604
Drug: JPI-547
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose levels will be escalated following a 3+3 dose escalation scheme.
Study: NCT04000919
Drug: 5HTP
Normalized name: GABA/5HTP/caf/arg/chl/br/hb318 1,400 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)
Study: NCT04000919
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03764618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00823940
Drug: GSK1362885
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 - 100mg of GSK1362885 or placebo
Study: NCT00823940
Drug: GSK1362885
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 - 600mg or placebo